By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Merrimack Pharmaceuticals Inc. 

101 Binney Street

Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-441-1000 Fax: 617-491-1386


Start Up


Dyax Corp.  Antibody phage display

Company News
Battle of the Biotech Bands: Momenta (MNTA), PerkinElmer (PKI), Ironwood (IRWD) Will Try to Take Merrimack (MACK)'s Rock Crown 5/19/2015 9:17:02 AM
Merrimack (MACK) Announces Presentations At The 2015 ASCO Annual Meeting 5/14/2015 11:22:21 AM
Merrimack (MACK) Reports First Quarter 2015 Financial Results 5/8/2015 6:47:17 AM
Merrimack (MACK) Announces Initiation Of A Phase 2 Front-Line Clinical Trial Of MM-141 In Biomarker-Selected Patients With Metastatic Pancreatic Cancer 5/5/2015 6:15:37 AM
Baxter BioScience Corporation (BAX) And Merrimack (MACK) Announce Filing For European Approval Of MM-398, An Investigational Treatment For Post-Gemcitabine Metastatic Pancreatic Cancer 5/4/2015 11:29:20 AM
Merrimack (MACK) Announces Timing Of First Quarter 2015 Investor Conference Call And Presentation At Credit Suisse 2015 Antibody Conference 4/29/2015 11:09:48 AM
PharmaEngine, Inc. Announces Merrimack (MACK) Completed MM-398 (PEP02) New Drug Application Submission To U.S. FDA 4/28/2015 10:37:15 AM
Merrimack (MACK) And Baxter BioScience Corporation (BAX) Announce Completion Of New Drug Application Submission To U.S. FDA For MM-398 As A Treatment For Post-Gemcitabine Metastatic Pancreatic Cancer 4/27/2015 6:53:49 AM
Merrimack (MACK) Release: First-in-Human Phase 1 Trial Of MM-141 Demonstrates Activity In Biomarker Positive Patients 4/21/2015 11:28:40 AM
Merrimack (MACK) Announces Final Clinical Results For MM-302 Phase 1 Study Demonstrating Robust Activity In Heavily Pre-Treated Patients With HER2-Positive Metastatic Breast Cancer 4/21/2015 9:49:29 AM